Case Report: Durable therapy response to Osimertinib in rare EGFR Exon 18 mutated NSCLC

Up to 20% of all non-small cell lung cancer patients harbor tumor specific driver mutations that are effectively treated with tyrosine kinase inhibitors. However, for the rare EGFR deletion-insertion mutation of exon 18, there is very little evidence regarding the effectiveness of tyrosine kinase in...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	Michael Cekay, Philipp F. Arndt, Rio Dumitrascu, Rajkumar Savai, Andreas Braeuninger, Stefan Gattenloehner, Dagmar Steiner, Fritz Roller, Khodr Tello, Katja Hattar, Werner Seeger, Ulf Sibelius, Friedrich Grimminger, Bastian Eul
Формат:	Artigo
Хэл сонгох:	Inglês
Хэвлэсэн:	Frontiers Media S.A. 2023-08-01
Цуврал:	Frontiers in Oncology
Нөхцлүүд:	non-small cell lung cancer EGFR mutation tyrosine kinase inhibitors (TKIs) Osimertinib EGFR Exon 18 insertion
Онлайн хандалт:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1182391/full
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!